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8INTRODUCTION
9INTRODUCTION:
The pancreas is among the top ten most common sites of new
cancers, but pancreatic cancer is the fifth leading cause of cancer deaths
among Indian population, being responsible for 5%[5] of all cancer-related
deaths.Pancreatic cancer is known to be difficult to diagnose in its early
stages. At the time of presentation, nearly 50% of all patients have distant
disease[5] and 25% have regional spread[5]. The predicted 1-year survival
rate for pancreatic cancer is only 25%, and the calculated 5-year survival is
7%[5].The head of the pancreas is the most common site for occurrence of
cancer and when within 2 cm. from the ampulla presents as periampullary
carcinoma with obstructive jaundice.
Cancer antigen 19-9 (CA 19-9) is a tumor-associated mucin
glycoprotein antigen that is related to the Lewis blood group protein[37].
This antigen is present in epithelial tissues of the pancreas, biliary ductular
cells, stomach, gall bladder, colon, endometrium, salivary glands, and
prostate[29]. Normal pancreatic juice, bile (in benign conditions), and even
seminal fluid contain CA 19-9[18]. Blood levels may be elevated in healthy
patients as well as in patients with benign and malignant conditions[6] .Its
sensitivity (68-93%) and specificity (76-100%)[43] are inadequate for
accurate diagnosis.Nonetheless when a diagnosis is made, it can be used to
predict the extent of the disease and outcome after surgical resection.
10
REVIEW OF LITERATURE
11
BRIEF HISTORY:
Heterophilus,a Greek surgeon first described pancreas.
Wirsung identified the pancreatic duct in 1642.
Pancreas as a secretory gland was described  by Graaf in 1671.
Morgagni 1769 first described pancreatic adenocarcinoma.
Kausch first two stage pancreaticoduodenectomy in 1912.
Brunschwig did the first radical pancreaticodudenectomy in 1937.
The first pancreatico-duodenectomy was done in one stage by Whipple in
1940.
ANATOMY:
GROSS ANATOMY:
The pancreas is a soft, yellow, glandular structure measuring
approximately 20 cm in length and weighs about 95 g.It lies posterior to
the stomach at the level of the second lumbar vertebra[13]. The organ is
covered by peritoneum anteriorly, where it forms the floor of the lesser
sac, and it is partially fixed to the retroperitoneum posteriorly. The
retroperitoneal nature of the pancreas and its central position in the middle
of the major abdominal blood vessels create some complicated anatomic
relationships, as well as challenging surgical exposure. The pancreas also
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has an intimate relationship with the second portion[18] of the duodenum, in
which the two organs share a common blood supply, which makes their
surgical separation generally impractical.
ANATOMIC DIVISIONS:
HEAD:
The head is the largest component of the pancreas, and it is located
in the C loop of the duodenum[28] .The anterosuperior portion of the head
is bordered by the antrum of the stomach and the first portion of the
duodenum. The right lateral portion is bounded by the second part of the
duodenum, and the left lateral extent ends at the neck of the pancreas. The
inferior border is bounded by the third portion of the duodenum. The flat
anterior surface forms the posterior extent of the lesser sac with a bare area
intervening where the omental bursa of the transverse colon is attached[28] .
These peritoneal layers contain middle colic artery, which arises from the
superior mesenteric artery.[19]
UNCINATE PROCESS:
The uncinate process of the pancreas is a continuation  of the head,
which arises from the original ventral pancreatic bud[19]. It lies
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posteromedial to the head.It is variable in size and position, and it is
interposed between major vascular structures in two different planes. It
separates the inferior vena cava and the portal vein in the dorsoventral
plane[8] . The aorta and the superior mesenteric artery are separated in the
sagittal section. The uncinate process lies adjacent to the superior
mesenteric artery, or it may completely encompass it[8]. An anomalous
right hepatic artery which originates from the superior mesenteric artery
may pass through it.
NECK:
The neck is the smallest part of the pancreas, and it is 1.5 to 2.5 cm
long. It lies directly over the portal vein, that creates a groove over its
posterior surface, as well as the superior mesenteric pedicle. Although
generally  lateral tributaries from the parenchyma of the neck to the
superior mesenteric vein are present, anterior tributaries are rare. This
allows an avascular plane to bedissected between the neck and the superior
mesenteric-portal vein.. The neck is that portion of the pancreas that is
usually divided during a pancreaticoduodenectomy for a lesion in the
pancreatic head.
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BODY:
The neck continues towards the left as the body of the pancreas,
which begins lateral to the superior mesenteric artery. It is related
superiorly to the splenic artery. Anteriorly, the body forms the floor of the
lesser sac. The splenic vein forms a posterior relation  to the body, where it
is embedded in the pancreatic parenchyma. The inferior margin of the
body provides an  attachment of the transverse mesocolon to the posterior
abdominal wall.
TAIL:
The body continues as the tail of pancreas which extends toward the
splenic hilum. The tail is differentiated from therest of the pancreas by its
mobility  It usually lies within the lienorenal ligament. The position of the
tail with respect to the hilum is not consistent, and it may reach the spleen
in only 50% of individuals.
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PANCREATIC DUCTS:
The ductal anatomy of the pancreas shows two named ducts: the main
pancreatic duct (Wirsung) and the accessory pancreatic duct (Santorini)[20].
The main duct begins at the tail of the pancreas and runs close to the
posterior surface of the pancreas,midway between the superior and inferior
borders to reach the head[20] . Under normal circumstances, the diameters
of the duct average 2.4, 3.5, and 4.8 mm in the tail, neck, and head,
respectively. Approximately 18 to 20 tributaries enter the main duct at
right angles along its course;[13] there also are additional inconsistent
tributaries from the uncinate process. Once the duct passes over the
superior mesenteric-portal vein confluence[16] in the neck of the pancreas it
enters the head, and it takes a more posterior course to eventually join the
common bile duct. Both finally end int the majordudenal papilla.
The anterosuperior portion of the pancreatic head  is drained by the
accessory pancreatic duct[9], which empties through the minor duodenal
papilla (70%) or into the main pancreatic duct. The accessory duct has a
demonstrable communication wit the main duct in the majority of patients.
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AMPULLA OF VATER:
The ampulla of Vater is the dilated distal confluence of the
pancreaticobiliary ductal system[46]. An ampulla exists only when the two
ducts join far enough from the papilla. The greatest diameter of a normal
duct is between 3 and 4.5 mm near its termination in the duodenum. The
duct is tapering towards the tail.
DUODENAL PAPILLA:
The major papilla (the papilla of Vater) lies on the posteromedial
wall of the second part of the duodenum[8] or, rarely, the third portion. The
papilla usually lies 7 to 10 cm distal to the pylorus, approximately at the
level of the L 2.
The minor papilla drains the accessory pancratic duct, and it usually
lies 2 cm cranial to the major papilla. The minor papilla lies distal to the
point where the gastroduodenal artery crosses behind the duodenum.
ARTERIAL SUPPLY:
The pancreas relies on a dual arterial blood arising from the celiac
trunk and the superior mesenteric artery. [9]
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The head of the pancreas, the uncinate process, and the C loop of
the duodenum share an anastomosing blood supply. The gastroduodenal
artery arises from the hepatic artery proper and gives off the superior
pancreaticodudenal artery[36] which gives off anterior and posterior
branches. They supply the head of the pancreas and the second portion of
the duodenum. The inferior  pancreaticoduodenal artery arises as the first
tributary of the superior mesenteric artery [13] as it emerges from the lower
border of the pancreas. These two vessels anastomose freely, and this
makes it difficult to surgically separatethe two structures.The rest of the
pancreas is also fed by a dual blood supply. The splenic artery,gives off its
first major branch the dorsal pancreatic artery, near the inferior edge of the
gland,this artery divides into two branches. One travels to the right and
connects with the anterior superior pancreaticoduodenal artery. The other
is the transverse pancreatic artery[13] , which runs towards the,nourishing
the body and the rest of the tail.
VEINS:
The veins usually lying superficial to the arteries and parallel them. The
veins srain into the superior and inferior mesenteric veins, the splenic vein,
and finally into the portal system.[15]
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The head and uncinate process of the pancreas have four
pancreatoduodenal veins[15]. The anterior superior pancreatoduodenal vein
drains into the right gastroepiploic vein, which is atributary of the superior
mesenteric vein. The posterior superior pancreatoduodenal vein drains
directly into the portal vein[9]. Both the inferior anterior and posterior
pancreatoduodenal veins empty into the superior mesenteric vein.
Tributaries seldom enter the superior mesenteric or portal vein from their
anterior surface[15] .The body and tail of the pancreas is drained by the
splenic vein,and the transverse pancreatic vein, which may empty into the
superior mesenteric, inferior mesenteric, or, sometimes, splenic vein[19].
LYMPHATICS:
The lymphatic drainage pattern of the pancreas includes five routes
of drainage.While the superior nodes arising from the anterior and
posterior portions of the pancreas, drain into the lymph nodes on the
superior surface of the pancreas[27] . the inferior collecting trunks
terminate in lymph nodes along the inferior border.Anterior collecting
trunks terminate in the infrapyloric and anterior pancreatoduodenal lymph
node. The posterior surface, empties into the corresponding posterior
lymph nodes. The lymphatics from the tail drain into splenic hilar lymph
nodes.
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NERVES:
The pancreas is innervated by both the sympathetic and
parasympathetic nervous systems from the splanchnic and vagus nerves,
respectively[9]. Efferent motor fibers innervating the ducts, acini, and blood
vessels are provided by both divisions. In the sympathetic division,
preganglionic fibers are provided from the greater and lesser splanchnic
nerves, whereas the celiac plexus contains the efferent fibers from the
pancreas.The parasympathetic nervous system primarily innervates the
pancreas via the celiac branch of the posterior or right vagus.
HISTOLOGY:
Pancreas consists of both exocrine and endocrine units termed acini
and islets of Langerhans, respectively. The acinar cells are arranged in
rounded structures and are pyramidal. These cells contain  zymogen
granules and the cell bodies of the postganglionic parasympathetic neurons
are interspersed between the acinar cells. The pancreatic acinar and duct
system secretes about 1 L of fluid per day that is rich in digestive enzymes,
sodium, and bicarbonate.
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The islets of Langerhans constitute 1 to 2% of the pancreatic massThe
various hormones secreted in the pancreas are
insulin,glucagon,somatostatin,pancreatic polypepetide.
EMBRYOLOGY:
The pancreas is formed from two separate buds arising from the
endodermal lining of the duodenum. The ventral bud appears first at about
the third week. The ventral bud forms the uncinate process and the lower
part of the head of the pancreas[22] . The remainder of the gland usually
arises from the dorsal bud. The main pancreatic duct arises by the fusion of
the ductal components . Failure of fusion occurs 10% of the time, causing
a persistent double duct system known as pancreas divisum. This rarely
causes pancreatitis.
The islets of Langerhans arise in the pancreatic parenchyma during
the third month of life. These islands of cells are present throughout the
gland. Insulin secretion begins roughly at the fifth month.
21
INCIDENCE:
Adenocarcinoma of the pancreas remains a relatively incurable
disease despite advances in surgical care of the resected patient, the move
toward enrolling patients in clinical trials, and advances in systemic
treatment for other solid tumors of the gastrointestinal tract.
Characteristically, patients present late in their disease with minimal vague
symptoms. The combination of aggressive tumor biology and ineffective
therapies usually results in the rapid decline of these patients, resulting in
death within a few months after diagnosis. Survival from this disease is
poor with approximately 23% of patients alive 12 months following
diagnosis and 5% alive at 5 years[34]. Men are more commonly affected
than women,mortality rates range from 7 to 9  per 100,000 for men and 4.5
to 6 per 100,000 for women[42] .It is a disease of the elderly. Only 10% of
patients  present before the age of 50, while those aged 50 to 54 experience
an incidence of 9.8 per 100,000, and those 70 to 74 an incidence of 57 per
100,000. The median age of diagnosis with pancreatic cancer is 72, with
less than 13% of cancers diagnosed prior to the age of 55 and greater than
69% of cancers diagnosed after the age of 65.
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GENETICS OF PANCREATIC MALIGNANCIES:
Four categories of mutated genes play a role in the pancreatic
tumorigenesis: oncogenes, tumor-suppressor genes, genome-maintenance
genes, and tissue maintenance genes[40]. Some of these mutations are
germline but those genetic mutations acquired during life, termed somatic
mutations, contribute to tumorigenesis within a tissue but are not passed to
offspring.
TUMOR SUPPRESSOR GENES:
Tumor suppressor genes are mainly involved in regulating the cell
cycle and blocking uncontrolled cell proliferation. Deletion, mutation,
chromosomal rearrangements are methods by which genetic alterations can
occur and hence result in an unregulated cell cycle. At least genes in this
group are known to be involved in the development of pancreatic cancer,
they include[1]
p16
p53
DPC4
BRCA2
MKK4.
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ONCOGENES:
Oncogenes are products of precursor proteins known as proto
oncogenes which get activated by mutation.Most commonly involved
genes are
K-RAS
BRAF
DNA MISMATCH REPAIR GENES:
DNA mismatch repair genes code for protein products which make
amends for the various discrepancies that would take place when DNA is
replicating[1]. When these repair genes are rendered mutant, flaws
encountered  in DNA sequences are left unrepaired. One such example is
in the case of RER+ (replication error-positive) tumors.[40]
GROWTH FACTORS:
Contributory evidence exixts to suggest that the increased
expression of some of the peptide growth factors play a significant part in
the initiation and biological behaviour of the tumor. These factors can act
either in an autocrine or paracrine fashion.The important ones are:[1]
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EGFR
TGF-beta
FGF
IGF
EPIDEMIOLOGY AND RISK FACTORS:
Adenocarcinoma is the most common malignancy of the pancreas.It forms
more than three fourths of all  tumors of the pancreas.[12]
DEMOGRAPHIC FACTORS:
 Increasing age is an important risk factor for pancreatic cancer, with
more than four fifths of the cases occurring in patients in the 60-80
years age group.[16]
 The gender distribution of pancreatic cancer is not particularly
remarkable,but males are more commonly affected by the disease.
 The risk is increased among the black population and is around 3
times higher than in the white population.
HOST FACTORS:
The most important host factors are the six genetic syndromes. These
syndromes are:[1]
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 hereditary nonpolyposis colorectal cancer (HNPCC)
 familial breast cancer associated with BRCA-2 mutations
 Peutz-Jeghers syndrome
 ataxia-telangiectasia syndrome
 familial atypical multiple mole-melanoma syndrome (FAMMM)
 hereditary pancreatitis.
Chronic pancreatitis, has been stated as an important risk factor for the
development of pancreatic cancer . [5] There is enough evidence to suggest
that when the diagnosis of chronic pancreatitis and pancreatic cancer are
separated by an interval of less than 10 years,it might be an important risk
factor . This might  suggest that chronic pancreatitis is an early indicator of
an undiagnosed occult pancreatic cancer.
The association between pancreatic cancer and diabetes is
inconclusive. Studies have demonstrated that diabetes is an important risk
factor only when the diagnosis precedes that of pancreatic cancer within 5
years and when patients are diagnosed after the age of 40 years. These data
suggest that more than a causal association,  recently diagnosed diabetes is
an early symptom of pancreatic cancer.[1]
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Other possible host factors that might have a role are thyroid tumors,
other benign endocrine tumors, and cystic fibrosis.[1]
ENVIRONMENTAL FACTORS:
 Cigarette smoking
 Foods rich in carbohydrate,triglycerides,salted foods
 Alcohol
 coffee
PATHOLOGY:
Ductal adenocarcinoma, the most common primary pancreatic malignancy,
accounts for approximately 80 % of all primary nonendocrine cancers.
[1]The region wise incidence is:
65% -head,neck,uncinate process
15%-body and tail
20%-diffusely distributed throughout pancreas
On cut section, adenocarcinomas are whitish ,poorly demarcated lesions
that often cause stricturous narrowing of the distal common bile duct.[19]
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Because of  the intense infiltrative nature, identifying the exact size of the
tumor intraoperatively is seldom possible. Microscopic analysis often
shows that the tumor often extends outside of the grossly demarcated
mass. On histologic analysis, infiltrative glandular components surrounded
by a severe fibrotic reaction are noticed. The epithelial cells often contain
mucin and are thrown into multiple papillary and cribriform structures.
These tumors characteristically demonstrate lymphovascular, perineural
invasion and this might suggest a poor outcome.
Adenocarcinomas, are rapidly growing tumors; most tumors that are
removed would have already spread through the lymphatics to regional
lymph nodes. In addition, these tumors directly infiltrate the various
adjacent  intraperitoneal and retroperitoneal structures . At the time of
death, up to four fifths of them have metastatic lesions in the liver,three
fifths have peritoneal implants, nearly half of them have lesions in the
lungs or pleura, and one fourth have deposits in the adrenal glands.
Adenosquamous is a variant with mixed contributions from both
histological varieties. It is common among patients who have received
chemotherapy+ radiation and has tumor properties similar to
adenocarcinoma.
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SYMPTOMS AND SIGNS:
The clinical presentation of pancreatic cancer depends on the
location of the tumor within the gland, with most symptoms initially
appearing vague and nonspecific.The majority of pancreatic tumors
develop in the region of the head, subjecting the pancreatic portion of the
bile duct to occlusion .[8] Jaundice is, therefore, the first presenting
symptom and may be associated with pruritus, clay coloured  stools and
high coloured urine.It may have been associated with previous episodes of
biliary colic, anorexia, or vague gastrointestinal distress. Patients with
pancreatic cancer initially develop a vague epigastric pain radiating to the
left subscapular region.Loss of weight, appetite, other systemic
manifestations like anorexia, myasthenia, and alternating constipation and
diarhhoea are seen in many patients. Nausea and vomiting,indicate early
gastric outlet/duodenal obstruction and may be a sign of locally advanced
disease.
Some tumors of the pancreatic head or body will not involve the bile
duct but may invade the duodenum or neural structures, including the
celiac or mesenteric plexi. Such invasion results in pain that may be
characterized by aching, pressure, or burning. Tumors in the head of the
pancreas, located off the midline to the right, may lead to pain in the right
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upper quadrant or epigastric area. Tumors involving the pancreatic body
usually lead to midepigastric pain, and those in the tail often cause left-
sided abdominal pain. Back pain is more suggestive of infiltration of the
retroperitoneum.
Pancreatic exocrine insufficiency manifested by steatorrhea occurs
relatively infrequently as a presenting symptom, and while it is often
initially mild and easily manageable, it may worsen after surgical resection
or radiation therapy. Pancreatic ductal obstruction may lead to acute
pancreatitis, which is occasionally a presenting sign of pancreatic cancer.
When a patient without risk factors for pancreatitis experiences an acute
attack, an underlying pancreatic cancer should be considered and
thoroughly investigated. Importantly, it is increasingly recognized that
glucose intolerance or overt diabetes is found  in up to 70% of patients,
and when diabetes develops in an older adult or when it is found in
conjunction with other symptoms such as pain, anorexia, or weight loss,
the possibility of an underlying pancreatic neoplasm should be raised.[33]
Other symptoms of pancreatic cancer include superficial or deep venous
thromboses, anorexia, or weight loss. In some studies, weight loss is the
most common symptom of pancreatic cancer. Unfortunately, initial
symptomatology, to include weight loss, may be indicative of metastatic
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disease, such as night sweats, significant fatigue, or liver pain. Gastric
outlet obstruction, increasing abdominal girth from ascites, and skin
manifestations all occur in pancreatic cancer, but are fairly uncommon as
presenting signs and symptoms.
Patients with pancreatic cancer usually have an unremarkable
physical examination, but the most common abnormal physical finding is
jaundice, which may be accompanied by cutaneous excoriations related to
pruritus. In patients with advanced disease, temporal muscle wasting,
hepatomegaly or a nodular liver, left supraclavicular lymphaadenopathy
(Virchow's node), deposits around the umblicus (Sister Mary Joseph's
nodules), or the unusual finding of metastasis at Blumer's shelf may be
discovered on digital rectal examination.[1]
PROGRESSION OF PANCREATIC CANCER:
Pancreatic ductal adenocarcinoma arises from ductal epithelial cells.
Neoplasia arising from these cells progress from initial intraductal
proliferative lesions to invasive carcinomas similar to other carcinomas
from ductal epithelium, such as breast ductal carcinoma or prostate cancer.
Pancreatic intraepithelial neoplasm (PanIN) is the term established for
intraductal proliferative epithelial lesions. This replaces old nomenclature
such as metaplasia, dysplasia, hyperplasia, and carcinoma in situ. PanINs
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are graded as 1A, 1B, 2, and 3 as they advance along a histologic
continuum of progressive dysplasia.The evidence that these lesions are
precancerous include the observation that following segmental resection of
pancreata with PanINs in the resected tissue, pancreatic cancer can develop
in the pancreatic remnant.
STAGING:[3]
PRIMARY TUMOR (T)
TXPrimary tumor cannot be assessed
T0 No evidence of primary tumor
TisCarcinoma in situ (also PanIN 3)
T1 Tumor limited to pancreas, 2 cm or less in greatest dimension
T2 Tumor limited to pancreas, more than 2 cm in greatest dimension
T3 Tumor extends beyond the pancreas but without involvement of the
celiac axis or the superior mesenteric artery
T4 Tumor involves the celiac axis or the superior mesenteric artery
(unresectable primary tumor)
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REGIONAL LYMPH NODES (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
DISTANT METASTASIS (M)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
STAGE GROUPING
Stage 0 Tis N0 M0
Stage IA T1 N0 M0
Stage IB T2 N0 M0
Stage                 IIAT3 N0 M0
Stage IIB T1 N1 M0
T2 N1 M0
T3 N1 M0
Stage  III T4 Any N M0
Stage   IV Any T Any N M1
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Another staging system has been proposed by the Japan Pancreas
Society ( Table-1 ), including other factors such as serosal invasion (S
factor), retroperitoneal invasion (RP factor), and portal vein invasion (PV
factor).
Table 1 -- Japan Pancreas Society Stage Classification [2]
Stage Grouping T S RP PV N M 5-Yr Survival
Stage I T1 S0 RP0 PV0 N0 M0 35–45%
Stage II T2 S1 RP1 PV1 N1 M0 15–25%
Stage III T3 S2 RP2 PV2 N2 M0 5–15%
Stage IV T4 S3 RP3 PV3 N3 M1 0–10%
Tumor (T)
T1 = 0 to 2 cm
T2 = 2.1 to 4 cm
T3 = 4.1 to 6 cm
T4 = >6.1 cm
Serosal invasion (S); Retroperitoneal invasion (RP); Portal venous
invasion (PV)
0 = Absence of invasion
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1 = Suspected invasion
2 = Definite invasion
3 = Severe invasion
Lymph nodes (N)
N0 = No metastasis
N1 = Primary lymph node group metastasis
N2 = Secondary lymph node group metastasis
N3 = Tertiary lymph node group metastasis
Distant metastasis (M)
M0 = No distant metastasis
M1 = Distant metastasis
INVESTIGATIONS:
SERUM BIOCHEMISTRY:
Serum total and direct bilirubin, ALP,GGT,5’ nucleotidase  values are
raised.The levels of hepatic transaminases may be unremarkable or may be
mildly elevated owing to acute liver injury. Coagulation profile may be
deranged due to hepatocellular dysfunction . Decreased enterohepatic
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circulation results in malabsorption of fat-soluble vitamins A,D,E,K and
subsequent defeciency of vitamin K-mediated coagulation products. Low
albumin levels, normocytic anaemia are present.
IMAGING MODALITIES:
With advances in imaging modalities,the set goals for the use of various
investigations are as follows:
(1) exploration can be limited to those patients with a high likelihood of
resection,
(2) objective criteria can be utilized to assess resectability rather than
subjective imprecise tactile perception,
(3) patients who will require venous reconstruction at time of resection can
be identified, optimizing preoperative planning,
(4) patients may move on to neoadjuvant therapy appropriate for their
stage of tumor without an initial exploration, and
(5) patients exhibiting an advanced tumor can be palliated with less
morbid nonoperative procedures.
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ULTRASONOGRAPHY:
Ultrasonography in pancreatic cancer, as in other diseases, is
particularly operator dependent, and in experienced hands may safely
replace assessment with helical CT.It is used as an initial creening image
to localise the lesion in a case of obstructive jaundice.It remains the most
important screening test to analyse the anatomical  origin of the disease
owing to its sensitivity in demonstrating a dilated  biliary system in cases
of obstructive jaundice. It also provides details regarding liver surface
deposits, mass lesion, peripancreatic lymph nodes, free fluid, Ultrasound
scans reveal a pancreatic mass in well over 50 % of patients with
pancreatic cancer. Nevertheless, a negative scan does not definitively rule
out pancreatic cancer.
Computerised Tomography(CT SCAN):
CT scanning is the most commonly used imaging modality for
confirmation of the diagnosis and for staging. Standard CT scans are
incapable of predicting the operability of the tumor. Nevertheless, major
vessel infiltration and hepatic metastases can be best  assessed with newer
techniques. Currently,the standard is the multiphase CT scan, coordinating
iv contrast  with serial films in arterial, portal venous, and parenchymal
phases .[4] This must be obtained on a helical CT scanner, allowing
acquisition during a single breath-hold for each phase. With this type of
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CT, extension of the tumor to the superior mesenteric artery (SMA), celiac
axis, superior mesenteric vein/portal vein (SMV-PV) complex, and
contiguous structures can be clearly determined as well as an assessment
of distant metastasis.
Resectability is defined on multiphase CT by[4]
(1) the absence of extrapancreatic disease
(2) patency of the SMV-PVconfluence
(3) SMA abutment-involvement less than 180 degree.
Distortion of the fat plane between the mass and the SMV-PV identifies
tumor invasion of the vein or fibrosis and defines the patient who may
require a vein reconstruction at the time of resection.The accuracy of CT
scan in predicting operability of a pancreatic cancer ranges from 80-90%.
Subcentimetric tumors can be missed, and a dilated biliary system
may be the sole report on CT. This should raise the suspicion of
malignancy and should be followed up by other investigations.
Optimally, CT imaging should precede stent placement and biopsy due the
possibility of postprocedure inflammation from the biopsy and artifact
from the stent that can confound interpretation of the images.
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Fig.1-This a CT SCAN picture  showing a hypodense lesion in the
head of pancreas with distended Gall bladder,dilated biliary
radicles,hypodense lesion in the liver suggesting metastasis.
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Fig 2-This CT scan shows a mass lesion in the head of pancreas,local
infiltration into first and second portions of duodenum,and
encasement of superior mesenteric pedicles.The disease was deemed
inoperable pre operatively based on CT.His CA 19-9 levels was 18
U/L.Only a palliative bypass procedure was done.
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ENDOSCOPIC ULTRASONOGRAPHY:(EUS)
EUS can image the primary cancer and be a means of obtaining a
FNA of pancreatic adenocarcinoma, but in general the procedure is
noncontributory when CT scan characterizes the tumor. When a mass
cannot be visualized on CT scan, sonography through the wall of the
stomach or duodenum can image tumors in the body/tail and head of the
pancreas, respectively. EUS is also used to get tissue samples by EUS
guided FNA. Although extremely sensitive in assessing the site,size,
extent and vascular invasion, EUS cannot be used to detect nodal status or
metastases and must hence be combined with CT or MRI scans.
MAGNETIC RESONANT
CHOLANGIOPANCREATOGRAPHY(MRCP):
Owing to motion artifacts, lack of bowel opacification, low spatial
resolution,long scanning times and low signal-to noise ratio, MRI has not
been shown to have a definitive advantage over modern CT scanning[1] .
Dynamic magnetic resonance imaging with rapid scanning sequences and
bolus iv contrast administration, may have sensitivity and specificity
comparable to those for helical CT[4] . The use of a
cholangiopancreatography might further increase the sensitivity but there
is no routine use of this imaging modality.
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ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY(ERCP):
ERCP once was a very sensitive diagnostic test for pancreatic
cancer[10]. The finding of an irregular stricture of varying lengths in the
pancreatic duct also known as "double-duct sign” is a telltale sign of
pancreatic malignancy . However, ERCP is no longer a diagnostic
investigation. ERCP is seldom used if operative intervention is
contemplated. Specific indications will include medically unfit or patients
with inoperable,terminal disease just for biliary decompression.
ERCP delineates pancreatic duct and common bile duct
anatomy.Brushings and ductal lavage are obtained and henceis a means of
obtaining cytologic diagnosis. But, similar to EUS, in the face of a
defining CT scan, its findings are often redundant. Pancreatitis, bleeding,
and perforation are severe complications associated with ERCP and
preclude the routine use of this modality in all
pancreatic cancer patients. ERCP should be reserved for patients in
need of endoscopic stenting, equivocal findings on standard evaluation, or
for patients in whom tissue diagnosis is needed, such as those in a clinical
study, with advanced disease, or those anticipating neoadjuvant therapy. If
anterior chemotherapy is being planned, an upper GI endoscopy would be
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the first investigation. During this procedure, biliary outflow can be
restored with the placement of an endobiliary stent, and EUS guided FNA
can also be performed.[4]
PERCUTANEOUS TRANSHEPATIC
CHOLANGIOGRAPHY(PTC):
This is another invasive technique of defining the biliary tree and
better defines the proximal biliary anatomy above the level of obstruction.
During this procedure a percutaneous biliary drain (PBD) can also be left
in place for the relief of cholangitis. The disadvantages of PTC are a result
of the more invasive nature of this technique and include bleeding,
hemobilia, and patient discomfort, as well as the inability to visualize the
pancreatic duct. For periampullary cancer, ERCP is more commonly used
than PTC or PBD.
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Fig 3-This MRCP image shows a  mass lesion in the head of pancreas
with dilated Common Bile Duct in the sagittal section.MRCP did not
show signs of locally advanced or metastatic disease.But his CA 19-9
level was 50,000 U/l.Nevertheless,  intraoperatively the  tumor was
completely resectable and a classical Whipple’s procedure.
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POSITRON EMISSION TOMOGRAPHY:(PET SCAN)
At present the role of PET scanning is not well defined for
pancreatic cancers. However, more recent reports support the conclusion
that FDG-PET imaging may have a supplementary role but PET scanning
is not currently used in patients suspected of pancreatic cancers as a
routine.
UPPER GI ENDOSCOPY:
Upper GI endoscopy is useful in the diagnosis of pancreatic cancers
when these lesions infiltrate the ampullary region. If visualized, it is
relatively straight-forward to obtain a biopsy . Additionally,
endoultrasound may be performed during this procedure to visualise the
ampulla and duodenum [18]. Fine-needle aspiration (FNA) of any suspected
lesions can be performed at the same time as endoscopic ultrasound if
tissue diagnosis is of benefit.
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Fig-4 This is a picture of an Upper GI endoscopy which shows a
growth in the region of the ampulla.The CT scan showed a mass lesion
in the head of pancreas which was locally advanced and had
infiltrated along the papilla to reach the periampullary region.
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STAGING LAPAROSCOPY:
Currently, routine use of laparoscopy is not warranted. Few patients
will have findings on laparoscopy that add to information found at CT
scanning. It is recommended that Laparoscopy be limited to select patients
with primary tumors greater than 2 cm in diameter, body or tail tumors,
equivocal findings of metastasis on CT, ascites, and subtle clinical or
laboratory findings such as hypoalbunemia, elevated CA 19-9, marked
weight loss, and pain with narcotic dependency. Using these criteria, the
subset of patients with advanced tumors not identified on CT scan can be
accurately assessed by laparoscopy, and patients likely to not have
additional findings can be spared the expensive, time-consuming
procedure.
TISSUE DIAGNOSIS:
In a patient with a pancreatic mass who appears resectable and is a good
operative candidate this still remains somewhat controversial.
Percutaneous pancreatic mass biopsies can easily be performed, but
malignancy cannot be ruled out in case of a negative smear[35]. They can be
performed safely with rare complications including, fistula, pancreatitis,
hemorrhage, abscess, tumor seeding and rarely death[10]. A negative biopsy
in a patient suspected of having pancreas cancer with a low operative risk
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and apparently resectable disease will not alter the decision to explore the
patient. Percutaneous biopsies should only be performed in patients
thought to have prohibitively high operative risks or who appear
unresectable and are being considered for either neoadjuvant or palliative
therapy. In special circumstances as a result of a patient presenting
imaging characteristics where lymphoma or metastatic disease from
another primary are suspected, percutaneous biopsy has value. These
diseases are often best managed without resection. FNA may be performed
at the same time as endoscopic ultrasound (EUS).
TUMOR MARKERS:
Tumor markers are indicators of cellular, biochemical, molecular, or
genetic alterations by which neoplasia can be recognized. These surrogate
measures of the biology of the cancer provide insight into the clinical
behavior of the tumor. This is particularly useful when the cancer is not
clinically detectable. The information provided may
• Be diagnostic and distinguish benign from malignant disease
• Correlate with the amount of tumor present (so-called tumor burden)
• Allow subtype classification to more accurately stage patients
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• Be prognostic, either by the presence or absence of the marker or by
its concentration
• Guide choice of therapy and predict response to therapy
The features of an ideal tumor marker: [32]
1. The marker is expressed exclusively by the particular tumor
2. Collection of the specimen for the tumor marker assay is easy.
3. The assay itself is reproducible, rapid, and inexpensive.
4. Currently, there is no one marker that fulfills all these criteria for
any cancer, nor is there any specific cancer in which there are
biomarkers that completely describe its behavior.
5. Tumor markers fall into three broad categories—proteins, genetic
mutations, and epigenetic changes. All three may be found in the
tumor tissue itself. Tumor markers found in body fluids, particularly
blood and urine, have the greatest potential for clinical application
because of the ease of access to these fluids for analysis and because
repeated sampling allows in vivo monitoring of the malignancy for
such features as disease progression or recurrence, metastasis, and
response to therapy.
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CLASSIFICATION OF TUMOR MARKERS:
RNA- Based Markers
Overexpressed/underexpressed transcripts
Regulatory RNA (e.g., micro-RNA)
DNA-Based Markers
Single-nucleotide polymorphisms (SNPs)
Chromosomal translocations—bcr-abl (Philadelphia)
Changes in DNA copy number
Microsatellite instability
Epigenetic changes (e.g., differential promoter region methylation)
Carbohydrate Antigen 19-9
Carbohydrate antigen 19-9 (CA 19-9) is widely used as a serum marker for
pancreas cancer, but its use is limited to monitoring response to therapy,
not as a diagnostic marker. It is a mucin-type glycoprotein expressed on
the surface of pancreatic cancer cells and was initially detected by
monoclonal antibodies raised against colon cancer cell lines in a mouse
model.[7] The CA 19-9 epitope is normally present within the biliary tree.
Biliary tract disease, both acute and chronic, can elevate serum CA 19-9
levels.
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TESTING:
CA 19-9 is detected with an immunoassay, and the upper limit of normal
for a healthy adult is 37 U/mL. Sensitivities of CA 19-9 in the diagnosis of
pancreatic cancer range from 67% to 92%, with specificities ranging from
68% to 92%.[7] The utility of CA 19-9 as a diagnostic marker is limited in a
number of ways. First, patients withLewis blood group negative antigen
cannot synthesize CA 19-9, and therefore is not used as a  marker in them,
who make up about 10% of the population. Second, patients with benign
biliary tract disease can have levels up to 400 U/mL, with 87% having
concentrations higher than 70 U/mL. Significant numbers of patients with
pancreatitis, either acute or chronic, also have elevated levels. Third, CA
19-9 levels are also elevated in those with other cancers, including those of
the biliary tree (95%), stomach (5%), colon (15%), liver (HCC, 7%) and
lung (13%). For colorectal cancer, CA 19-9 levels add little clinically
useful information to determination of CEA levels.
SCREENING:
It is not useful as a screening modality because of its low sensitivity in
early-stage disease. With increasing levels, the diagnosis of pancreatic
malignancy becomes more accurate. When a cutoff level of 100 U/mL is
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used, a number of studies have demonstrated that although sensitivity
ranges from 60% to 84%, specificity for pancreas cancer is 95% or greater.
Levels higher than 1000 U/mL are almost diagnostic of pancreatic cancer.
Because of its frequent elevation in benign biliary tract disease,it is not
useful in distinguishing benign from malignant distal common bile duct
strictures.
PROGNOSIS:
In patients with pancreatic cancer , the level of CA 19-9 has been shown
to correlate with tumor burden.[21] For example, higher levels typically
correlate with higher tumor stage, and more than 95% of patients with
unresectable disease have levels higher than 1000 U/mL. Of patients who
undergo curative resection, those whose CA 19-9 levels returned to normal
survived longer than those whose levels fell but never normalized.
MONITORING:
Serial measurement of CA 19-9 is used to monitor response to treatment.
A rise in CA 19-9 after curative resection has been shown to precede
clinical or computed tomographic evidence of recurrence by 2 to 9 months.
In patients with unresectable/metastatic disease, failure of CA 19-9 levels
to fall with chemotherapy reflects poor tumor response. However, in both
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settings, the lack of alternative effective therapies limits the utility of serial
monitoring of CA 19-9.
TREATMENT METHODS:
WHIPPLES PANCREATICODUDENECTOMY:
Exposure for a pancreaticoduodenectomy can be performed through a
midline laparotomy incision or a chevron incision can be used.
The first step of the pancreaticoduodenectomy is to assess the extent of
disease and resectability.After entering the abdomen thorough search for
deposits in the liver surface,pelvis,mesentry and parietal peritoneum is
done. An extended Kocherisation  is performed by creating a plane
between the retroperitoneum and duodenum+ head of the pancreas
allowing the visualization of the superior mesenteric artery at its origin
.The lesser sac is entered by dividing the gastrocolic omentum from the
colonic end and the tumor is held between the thumb and index finger and
the local extension is assessed.[26]
When the tumor is deemed resectable gall bladder is mobilised from
the fossa and a cholecystectomy is done.The common hepatic duct is
divided distal to the insertion of the cystic duct. The portal vein tunnelling
is done in the TUNNEL OF LOVE[6] ,in the retropancreatic groove.The
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portal vein is skeletonised from the neck of pancreas  upto the porta
hepatis.[8]The gastroduodenal artery is identified, clamped and ligated.
For a classic Whipple procedure, a distal gastrectomy is performed by
dividing at the level of D 1. In a pylorus-preserving
pancreaticoduodenectomy, the stomach is divided 2 to 3 cm distal to the
prepyloric vein of Mayo with a linear stapling device.[12] Distally the bowel
is divided 20 cm distal to the ligament of Treitz..[1]
The SMV PV confluence is identified and an avascular plane is developed
nterior to it after ligating the multiple small tributaries draining into the
SMV.Inadvertant injury to these vessels might cause torrential
intraoperative bleeding.Once the plane is created a penrose drain is passé
across at the level of neck of pancreas. Two stay sutures are taken ,one
superiorly and the other iinferiorly before  the pancreas is transacted at the
neck and the duct orifice in the pancreatic remnant is cannulated. More
stay sutures with 2 ‘0 silk are used in the remnant and a plan is being made
for reconstruction
There are multiple options for reconstruction after
pancreaticoduodenectomy. Most commonly the reconstruction first
involves the pancreas, then the biliary, and lastly the enteric.
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The first anastomosis is pancreatic either a pancreaticogastrostomy or
pancreaticojejunostomy.The pancreaticojejunostomy is done in an end to
end or end to side fashion using 2 ‘0 vicryl and 2 ‘0 silk in two layers.[12]
The pancreaticogastrostomy is usually done by the dunking method in two
layers.The next anastomosis is the hepaticojejunostomy done in a single
layer by the parachuting technique with 3’0 silk.The anastomosis is
positioned 10 to 15 cm distal to the pancreatic anastomosis. The continuity
of the bowel is established by a gastrojejunostomy 20 to 30 cm distal to the
bilioenteric anastomosis.The gastrojejunostomy is done in a
retrocolic,isoperistaltic fashion in 2 layers with 2 ‘0 silk and 2’0 vicryl.A
feeding tube is placed distal to all the anastomoses.Bilateral intraperitoneal
drains are placed and wound closed in layers.
The postoperative management consists of keeping the patient with
nothing by mouth for atleast 4 to 5 days. The stomach is decompressed
with a nasogastric tube which is positioned intraoperatively to drain the
bile.It is removed when the outpu falls below 500 ml. Feeding through the
jejunostomy tube is initiated by third post operative day as tolerated and
gradually stepped up till 2.5 litres. In case of suspicion of a leak DT
amylase is measured in relation to the serum amylase.The drains around
the pancreatic anastomosis are removed when there is no evidence of leak.
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Multiple theoretic justifications to place preoperative biliary stents exist,
including better delineation of the level of obstruction, reduction of
jaundice and pruritus, increased ease in performing the bilio enteric
anastomosis, prevention of biliary sepsis.[12] Currently stenting is done
only when indicated.
Fig 5-During initial assessment, during laparotomy ,multiple deposits
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Fig6- Surface deposits found in the liver,the disease was metastatic
and was inoperable.Only a palliative bypass was done. were found in
the mesentry and transverse mesocolon.The disease was metastatic
and only palliative bypass was done.
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Fig 7-Pancreas transacted at the neck after taking stay sutures
superiorly and inferiorly.The pancreatic duct is cannulated to allw
pancreatico jejuna anastomosis-duct to mucosa anastamosis.
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Fig 8- Roux loop is being constructed by dividing the vessels in the
mesentry and 20 cm from the DJ flexure is removed with the
specimen.
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Fig 9- Pancreatico jejunostomy ,the first anastomosis of whipples
procedure is being done in an end to end fashion in 2 layers.
60
Fig 10- Roux en Y hepatico jejunostomy done 15 cm distal to
pancreatico jejunostomy,done in single layer with 3’0 silk.
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Fig 11-Cut section of the specimen including distal stomach,gall
bladder with cystic duct,entire duodenum and first 20 cm of
jejunum.The instrument is pointing at the ampulla with a stent in
situ,which was placed preoperatively for biliary decompression.
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COMPLICATIONS:
The operative mortality rate for Whipples procedure  is currently less than
2% in centers specializing in pancreatic surgery.[2] Despite this, the
incidence of postoperative morbidity remains as high as 40 to 50%. The
two leading causes of postoperative morbidity are early delayed gastric
emptying and minimal leak or dehiscence at the pancreatic anastomosis
(pancreatic fistula). Delayed gastric emptying is seen in up to15% of
patients. Although not endangering and usually self-limiting, this condition
can prolong lengths of stay and increase hospital cexpenditure..
Erythromycin, a motilin agonist, may improve gastric emptying after
pancreaticoduodenectomy. Pancreatic fistula occurs in 10 to 20% of
patients after pancreaticoduodenectomy. [10]The pancreatic anastomotic
leak is usually managed by placing closed-suction drains close to the
pancreatic anastomosis, to make it a controlled fistula and to reduce the
risk of intra- peritoneal abscess. By definition, a pancreatic fistula usually
occurs 7 or more days postoperatively, when the output in the drainage
tubes contain milky, amylase-rich fluid of atleast 50 ml per day.[1]When
the amylase level in the drainage tube fluid is three times raised over the
serum amylase it is pathognomonic of pancreatic anastomotic leak. In
approximately 85% of patients, the pancreatic leak settles withconservative
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management, 10% will require image guided aspiration of the loculated
collection,5% may require exploration for adequate peritoneal lavage.
Other  significant complications[1] :
Wound infection
Intra-abdominal abscess
Cholangitis
Pneumonia
Bile leak
Pancreatitis
PALLIATIVE THERAPY:
With accurate preoperative staging, the resectability rate for
periampullary cancers is approximately 80%. When a patient undergoes
exploratory laparotomy (and sometimes exploratory laparoscopy) and is
found to be unresectable, a decision must be made as to whether to
operatively palliate the patient. Operative palliation is indicated in a patient
without widespread metastatic disease and with a relatively long life
expectancy. The added potential morbidity and mortality of operative
palliation must be weighed against the more durable palliation achieved
with hepaticojejunostomy and/or gastrojejunostomy. Additionally,
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chemical splanchnicectomy can be performed at the same time for relief of
pain.
Operative Palliation of Obstructive Jaundice:
The most commonly performed procedure for biliary decompression
is hepaticojejunostomy. Simple drainage through a T tube inserted above
the biliary obstruction should be avoided as this causes a high output
biliary fistula and results in major electrolyte abnormalities.
Hepaticojejunostomy provides more durable relief of obstructive jaundice
than does cholecystojejunostomy because of the proximity of the cystic
duct to most periampullary cancers. The hepaticojejunostomy is performed
after cholecystectomy in an end-to-side fashion to either a Roux limb or a
loop of jejunum with a Braun jejunojejunostomy between the afferent and
efferent limbs. Only 4% of patients with unresectable periampullary
cancers palliated with hepaticojejunostomies develop recurrent jaundice
prior to their deaths. As operative palliation is attempted more with
minimally invasive techniques, perhaps laparoscopic
cholecystojejunostomies will be performed more often secondary to the
relative ease with which they can be done and to avoid a major incision.
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Operative Palliation of Duodenal Obstruction:
Pancreatic cancers may cause gastric outlet obstruction by compromising
the duodenal lumen. Most patients with gastric outlet obstruction from a
pancreatic cancer that is not widely disseminated benefit from palliation,
whether operative or with endoscopic stenting techniques. There remains
controversy, however regarding the role of prophylactic gastrojejunostomy
in a patient who is being explored but without symptoms of gastric outlet
obstruction. The gastrojejunostomies were performed typically in a
retrocolic (to the left of the middle colic vessels) and isoperistaltic fashion,
using a loop of jejunum 20 to 30 cm beyond the ligament of Treitz.[6] The
gastrotomy is placed on the back wall of the stomach in the most
dependent portion. Vagotomy is not routinely done because it might
worsen the delayed gastric emptying, the limited life expectancy of the
patients, and the ability to control acid secretion medically.
Operative Chemical Splanchnicectomy for Pain:
The procedure is performed by injecting 20 mL of 50% ethanol or
saline through a spinal needle in the para aortic space at the level of the
celiac plexus. Even those patients who did not report pain preoperatively
derived benefit from the splanchnicectomy as they appeared to have a
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delay in the onset of their pain and had lower pain scores as their disease
progressed when compared to control patients.
Nonoperative Palliation:
Only 15–20% of patients with pancreas cancer are found to be
resectable[5] for cure at the time of presentation because of disseminated
disease or locally advanced diseaseFor the majority of patients, palliation
of symptoms is the primary goal of any invasive intervention,and the three
main problems that need to be palliated are obstructive jaundice, gastric
outlet obstruction, and pain.
Nonoperative Palliation of Obstructive Jaundice:
Nonoperative biliary drainage can be achieved either through a
percutaneous or an endoscopic approach. Percutaneous transhepatic
approaches are aided by the fact that the intrahepatic ducts are usually
dilated in patients presenting with obstructive jaundice. Endoscopic
drainage has the advantage of not having any external catheters. In a
randomized trial comparing endoscopic versus percutaneous stent
placement in 70 patients, the success rate, overall complication rate, and
procedure related mortality rate was significantly lower in the endoscopic
group. Endoscopic biliary stents may be either plastic or metal. Plastic
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stents are generally temporary and are available in different diameters and
lengths. Because of the limitations in the diameter of the accessory channel
of endoscopes, usually the largest plastic stent that can be placed is 12F.
This relatively small diameter results in frequent occlusion and the
necessity of periodically changing these stents. In an effort to improve on
the rate of stent occlusion, self-expanding metallic stents have been
developed and when deployed can reach a diameter of 30F. Randomized
controlled clinical trials comparing 10F or 11.5F plastic stents to 30F
metallic stents have shown metallic stents to have a longer patency rate
(6.2 to 9.1 months compared to 4.2 to 4.6 months) and to be associated
with lower rates of cholangitis, stent replacement/revision, and hospital
days. Metallic stents eventually fail because of tumor ingrowth at the ends
and through the interstices. Polyurethane-covered stents are currently
being developed and used and probably have better patency and results.
The disadvantage of metallic stents is that they cost more and should be
used in patients who are expected to live longer than 6 months.
Nonoperative Palliation of Duodenal Obstruction:
Until recently, duodenal obstruction in patients found to be unfit for
surgical bypass was treated with placement of gastrostomy tubes. The
development of expandable metallic bowel stents have provided an
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additional way of controlling gastric outlet obstruction in this group of
patients. Gastroduodenal stenting is successful in 80–90% of patients and
provides adequate relief of obstruction in most patients.
Nonoperative Palliation of Pain:
In addition to opioids and nonsteroidal anti-inflammatory agents,
several nonoperative palliative treatment modalities for pain with
periampullary cancers have been developed including ultrasound or CT-
guided celiac plexus nerve blocks and even external beam radiotherapy.
Several randomized controlled clinical trials comparing percutaneous
celiac plexus nerve blocks to standard oral analgesics have demonstrated
significant diminution in pain and narcotic use in the majority of the
patients.
ADJUVANT THERAPY:
In 1985, the Gastrointestinal Tumor Study Group (GITSG) trial was
published. This was a prospective randomized trial  to split-course
radiotherapy (4000 cGy, 20 fractions, over 6 weeks) with bolus 5-
flourouracil (5-FU) 500 mg/m2 [16]intravenous daily, each of the first three
days of radiation therapy of each 200-cGy sequence in patients with
pancreas cancer. Additionally, patient receiving adjuvant therapy received
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bolus 5-FU every week for 2 years. The patients on this trial who received
adjuvant therapy had better overall survival rates.
It has also been demonstrated that multiagent 5-FU based chemotherapy
regimens can be combined with radiotherapy. The various drugs which can
be used are cisplatin,interferon gama,gemcitabimne
NEOADJUVANT THERAPY:
Neoadjuvant therapy has several theoretical advantages. It allows
timely administration of chemo- or chemoradiotherapy to patients who are
at a high risk of residual or recurrent disease following surgical resection.
It has the potential to shrink the tumor and can decrease the extent of local
disease. Patients who develop dissemination during neoadjuvant treatment
are unlikely to gain advantage from surgical resection and are spared the
morbidity, and potential mortality of resection. It allows better patient
selection who are most likely to benefit from surgical resection
PALLIATIVE CHEMOTHERAPY:
Prior to the (FDA) approval of gemcitabine, the antimetabolite 5-
FU was considered standard therapy for advanced pancreatic cancer.
Although response rates greater than 30% were reported for treatment with
5-FU[17], most of these reports were based primarily on clinical tumor
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evaluation. But currently more modern phase II trials have reported
response rates less than 10% for 5-FU alone or with leucovorin.[11]
Gemcitabine is a nucleoside analogue that is sequentially
phosphorylated and incorporated into replicating DNA,and that would
cause premature chain termination.[11] Through use of this agent,
significant tumor shrinkage by more than 50% was achieved in only about
5% of patients, but a substantial subset of patients had sustained
alleviation of tumor-related symptoms.Trials are currently being conducted
by combining gemcitabine with other chemotherapeutic agents such as
topoisomerase I inhibitors, platins, and taxanes. Additionally, gemcitabine
is being combined with targeted therapy agents such as antiangiogenic and
epidermal growth factor receptor agents
IMMUNOTHERAPY:
Immune-based therapies can exploit both the cellular and humoral
components of the immune system. Strategies directed at the cellular
components recruit and activate T cells that recognize tumor-specific
antigens.[14] Strategies using monoclonal antibodies are being designed to
target tumor-specific antigens that can kill tumor cells by direct lysis or
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through delivery of a conjugated cytotoxic agent. Both approaches are
attractive for several reasons.
PROGNOSTIC FACTORS OF CARCINOMA OF PANCREAS:
The prognosis for patients with resected adenocarcinoma of the head of the
pancreas is predicted by multiple factors including[12]
 tumor stage
 biologic features
 molecular genetics
 degree of differentiation
 margin status
 nodal status
 perioperative factors
 the use of adjuvant chemoradiation.
In an analysis of long-term survivors with resected pancreatic
adenocarcinoma, the 5-year actual survival rates was 15% for pancreatic
cancers.
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CONCLUSION:
Pancreatic cancers represent significant clinical problems. Although
traditionally patients with these diseases had a dismal prognosis, proper
staging and patient selection have led to improved results. When possible,
surgical resection for cure should be attempted as this gives the only
chance of long-term survival. Surgical resection should be performed by
surgeons experienced in the management of these diseases and at centers
that can aptly care for these patients to minimize morbidity and mortality.
There are many developments on the horizon that have the potential to
improve the survival and well-being of patients with these diseases.
To summarise,tumor markers are generally helpful as part of a
diagnostic work-up, in prognosis, and as surrogates of tumor burden. In
pancreatic cancer, several tumors markers may be elevated including CEA,
the carbohydrate antigens (CA) 19-9, 50, and 242, CAM 17-1, and
DUPAN 2. Of these, CA 19-9 has emerged as the most clinically useful
marker. This antigen was originally defined by a monoclonal antibody
produced by hybridomas from mice inoculated with a human colon cancer
cell line. The epitope of this antibody is a sialylated lacto-N-fucopentaose
II related to the Lewis-a blood group antigen. This underscores the
limitations of CA 19-9. First, it is not specific for pancreatic cancer and
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has been found to be elevated in a number of other tumor types such as
biliary tract, colon, and stomach cancers. Second, roughly 10% of patients
are Lewis antigen-a or -b negative and unable to synthesize this antigen.
These individuals have undetectable levels of CA 19-9, even in the setting
of advanced pancreatic cancer.35 Furthermore, cholestasis can falsely
elevate serum CA 19-9 levels and, therefore, in patients who present with
obstructive jaundice, an elevated CA 19-9 is not specific for the presence
of pancreatic malignancy. Despite these caveats, serum CA 19-9 levels
appear to have prognostic utility, particularly when measured either
preoperatively and/or postoperatively in patients with resectable pancreatic
cancer. In addition, for patients with more advanced disease, a decrease in
CA 19-9 levels in response to therapy has been associated with better
survival.Although serum CA 19-9 levels have clinical utility in established
pancreatic cancer, its performance as a screening tool has been
disappointing.
In the evaluation of patients, preoperative CA 19-9 levels have been
used to predict patient outcomes. When blood levels of CA 19-9 were
greater than 1000 U/mL, 96% of tumors were found to be unresectable.
However, this preoperative evaluation alone has yet to be widely used to
establish inoperability.] Furthermore, several studies have shown a
correlation between a postoperative decline in CA 19-9 levels and the
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increased duration of patient survival. Patients whose CA 19-9 normalized
postoperatively may live longer , whereas rising CA 19-9 levels may
correlate with shorter survival time.Currently since inconclusive data
exixts regarding the value of CA 19 9 to predict the reseectability of tumor
in the head of pancreas it is imperative to do an analysis of the same in our
setting.
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AIMS AND OBJECTIVES
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AIMS AND OBJECTIVES:
The aim of the present study is
• To analyze the relation of the tumour marker CA 19-9 levels to the
stage of the disease in cancer head of pancreas and
• To evaluate its role in predicting the tumour resectability.
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MATERIALS AND
METHODS
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METHODS:
A proforma will be made that includes detailed history, physical
examination, basic investigations and other relevant investigations
required. All patients diagnosed with carcinoma head of pancreas on the
basis of CECT Abdomen  & Pelvis or MRCP,will be tested for serum
levels of  CA 19-9. On the basis o fthe mentioned inclusion and exclusion
criteria 30 patients who are eligible are included in the study.After
complete evaluation,  these patients are taken up for surgery with either
curative or palliative intent.The intraoperative findings, based on which the
resectability of the tumour is ascertained are
documented..Postoperatively,diagnosis is confirmed  by the
histopathological report of either the resected specimen(curative surgery)
or tissue sampling (palliative surgery). Subsequently ,the correlation
between the levels of CA 19-9 and the resectability of the tumour are
analysed.
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MATERIALS:
• Setting : Department of General Surgery,
Government Stanley Hospital,
Chennai
• Study design : RETROSPECTIVE  ANALYTICAL
STUDY
• Study period : 2 years
• Materials : 30 patients
• Inclusion criteria : Age 30-80 years
Both male and female patients
Patients with carcinoma head of
pancreas proven by CECT/MRCP
• Exclusion criteria : Patients not taken up for
surgery, either curative or palliative.
• Ethical committee clearance : Obtained
• Informed consent : Obtained
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RESULTS AND ANALYSIS
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Table 1:
SITE OF
MALIGNANCY
MALE FEMALE
HEAD OF PANCREAS 16 14
GENDER DISTRIBUTION
13
13.5
14
14.5
15
15.5
16
16.5
MALE FEMALE
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Table 2:
AGE
GROUP
31-40 41-50 51-60 61-70 71-80
NO.OF
PATIENTS
6 4 10 9 1
AGE DISTRIBUTION
0
2
4
6
8
10
12
31-40 41-50 51-60 61-70 71-80
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Table 3:
TUMOR MARKER <37  U/L >37   U/L
CA 19-9 21 9
DISTRIBUTION OF CA 19-9 LEVELS
21
9
Column1
<37
>37
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Table-4
NATURE OF
SURGERY
WHIPPLES
PROCEDURE
PALLIATIVE
BYPASS
NO.OF CASES 13 17
NATURE OF OPERATIVE PROCEDURE:
0
2
4
6
8
10
12
14
16
18
WHIPPLES
PROCEDURE
PALLIATIVE BYPASS
Series 1
Series 2
Series 3
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Table-5
LEVELS
OF
CA 19-9
PREOPERATIVELY
INOPERABLE
INTRAOPERATIVELY
INOPERABLE
TOTAL
NUMBER
OF
CASES
<37 6 6 12
>37 2 3 5
NUMBER
OF CASES 8 9 17
CA 19-9 LEVELS AMONG INOPERABLE CASES
0
1
2
3
4
5
6
7
<37 >37
PRE OPERATIVE
INTA OPERATIVE
Series 3
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Table-6
CA 19-9 OPERABLE INOPERABLE
<37 9 (70%) 12 (71%)
>37 4 (30%) 5 (29%)
CA 19-9 AMONG OPERABLE AND INOPERABLE CASES
0
2
4
6
8
10
12
14
<37 >37
OPERABLE
INOPERABLE
Series 3
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DISCUSSION:
CA 19-9 as a tumor marker has been proven to be useful in
predicting outcomes and in follow up of patients with carcinoma of head of
pancreas. With lack of definitive evidence regarding the role of CA 19-9 in
predicting operability in a case of carcinoma of the head of pancreas, I
have chosen to analyse the same in a prospective study including 30
patients who underwent surgery for carcinoma of the head of pancreas,
either curative or palliative.
In my study, it was observed that the incidence of pancreatic
malignancies were almost equal in both males and females. Of the 30 cases
16 were males and 14 were females, and hence no gender preponderance
noted.
Pancreatic malignancies continue to be a disease of the elderly, with
19 out of the 30 patients being in the age group of 51-70 years. There were
10 patients in the 51-60 group and 9 patients in the 61-70 years group.
As a part of the pre-operative evaluation Contrast enhanced CT
(CECT) of abdomen and pelvis and serum CA 19-9 levels were done
routinely. In the 30 patients with evidence of carcinoma of the head of
pancreas included in the study, CA 19-9 levels were elevated in 9 patients
89
and were within normal limits in 21 patients. A cut-off of 37 IU/L was
used.
When the 30 patients were taken up for surgery it was found that in
13 of the patients the malignancy was operable and they underwent
classical Whipples pancreaticodudenectomy. In the other 17 patients the
tumor was deemed inoperable and a palliative bypass procedure was done.
Among the 17 patients who’s tumor was inoperable,8 were diagnosed pre-
operatively with CECT/MRCP, and the other 9  were found to be
inoperable only during surgery.
Of the 13 patients who had operable tumors, CA 19-9 was elevated in 4
patients and was normal in the other 9 patients. Among the other 17
patients with inoperable tumors,CA 19-9 was elevated in 5 of the patients
and was within normal limits in the other 12 patients.
Among inoperable cases 70% had raised CA-19-9 and among
operable cases 30% showed raised CA 19-9. Hence CA 19-9 seems to be
insignificant predictor of tumor resectability .
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CONCLUSION:
 CA 19-9 as a tumor marker is a poor indicator of  the extent of the
disease and
 It is not a predictor of the resectability  of the tumor in the head of
pancreas.
LIMITATIONS OF THE PRESENT STUDY:
 The study includes data from the Dept of Surgery alone and
does not include those surgeries done in the Institute of
Surgical Gastro-Enterology. The same surgeries are done in
the SGE dept too. So the results may not reflect the whole
hospital’s performance although the sample population is the
same.
 A solely prospective study would have been much better than
to rely on 2 years of retrospective data as done in this study.
 Some patients were lost on follow-up.
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SIMILAR STUDIES
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SIMILAR STUDIES:
Safi F, Schlosser W, Falkenreck S, Beger HG.
Prognostic value of CA 19-9 serum course in pancreatic cancer.
Hepatogastroenterology. 1998;45:253-25
Schlieman MG, Ho HS, Bold RJ.
Utility of tumor markers
in determining resectability of pancreatic cancer. Arch Surg
2003; 138: 951-955; discussion 955-956
Kilic M, Gocmen E, Tez M, Ertan T, Keskek M, Koc M.
Value of preoperative serum CA 19-9 levels in predicting
resectability for pancreatic cancer. Can J Surg 2006; 49: 241-244
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ABSTRACT
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“THE ROLE OF CA 19-9 IN PREDICTING TUMOR
RESECTABILITY IN CARCINOMA OF THE HEAD OF
PANCREAS”
Background:
To study the role of CA 19-9 in predicting the resectability of the tumor in
the head of pancreas .During the management of pancreatic carcinoma,CA
19-9 are measured to monitor response to chemotherapy and early
detection of  local recurrence.Nonetheless ,its exact role in the preoperative
evaluation to assess the operability of the tumor is controversial.
Materials and Methods:
30 patients diagnosed with carcinoma of the head of pancreas on the
basis of CECT/MRCP during the study period of  2 yrears are included in
the study.During the preoperative evaluation of these patients ,CA 19-9
levels were measured and recorded.Patients who are medically unfit for
surgery or those who did not warrant operative palliation  are excluded
from the study.After adequate preoperative preparation patients are taken
up for surgery with either curative or palliative intent. During surgery the
operative findings on the basis of which operability of the tumor is
assessed, is documented and tabulated against corresponding values of CA
19-9.Then the diagnosis is confirmed based on the histopathological
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report.The operative findings and its relation to the CA 19-9 levels are
analysed and the results are interpreted.
Results:
Of the 30 patients who were operated, 13 patients had operable
tumors and underwent WHIPPLES procedure and 17 of them had
inoperable tumors and had to undergo palliative bypass procedures of
some form.Of the 30 patients CA 19-9 levels were elevated in 9 patients
and was normal in 21 patients.Among the 13 patients who had operable
tumors, CA 19-9 was raised in 4 patients and was normal in 9 patients . Of
the 17 patients who had inoperable tumors CA 19-9 was elevated in 5
patients and was normal in 12 patients.Among the 17 patients who had
inoperable tumors,8 were diagnosed preoperatively,and of them CA 19-9
levels were raised in 2 patients and normal in 6 patients.In the group of  9
patients who had inoperable tumors diagnosed intraoperatively,CA 19-9
was raised in 4 of them and was normal in the remaining 5 of them.
Conclusions:
This study brings us to the conclusion that CA 19-9 ,as atumor
marker has no role in predicting the  tumor resectability in carcinoma of
head of pancreas.
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Proforma
Role of CA 19-9 in predicting tumor resectability in
cancer head of pancreas
Investigator : Dr.APARNA .M.J, PGY3 – MS (Gen Surg)
Guide : Prof. Dr. P. Darwin, Chief, Unit S1
____________________________________________________________________________
Name : Age/Sex:
I.P. No. :
Address :
Contact no :
D.O.A: D.O.S :                                                  D.O.D:
History and Physical:
Investigations:
HEMAT LFT
HB T.BIL
PCV D.BIL
RBC AST
TC ALT
DC ALP
PLT T.PROTEIN
ESR S.ALB
RBS
FBS
PPBS
P.T - T/C
INR
B.UREA aPTT – T/C
S.CREAT S.CALCIUM
S.Na+ CA  19-9
S.K+ FOBT
S.Cl- BL.GROUP
S.HCO3-
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X RAY
USG
CT/MRCP
SCOPY
HISTOPATH
(FNAC/BIOPSY)
OTHER
OPINIONS:
PER OP DIAGNOSIS
OPERATIVE PROCEDURE
ANESTHESIA
FINDINGS
DRAINS
BLOOD LOSS
SPECIMEN FOR HPE
POST OP HPE REPORT
POST OP COURSE
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Role of CA 19-9 in predicting tumor resectability in cancer
head of pancreas
Investigator : Dr.APARNA .M.J, PGY3 – MS (Gen Surg)
Guide : Prof. Dr. P. Darwin, Chief, Unit S1.
____________________________________________________________________________
Patient Information Module
You are being invited to be a subject in this study.
Before you participate in this study, I am giving you the following details about this
trial, which includes the aims, methodology, intervention, possible side effects, if any and
outcomes:
All patients diagnosed with cancer head of pancreas on the basis of CECT  or MRCP
will be included in this study. A detailed clinical history will be taken following a standardized
proforma. A detailed clinical examination will be made and relevant investigations, basic and
special investigations including CA 19-9 will be done.After complete evaluation,patients will
be posted for surgery with either curative or palliative intent.During surgery a complete
assessment of the extent and resectability of the tumour will be made and all the findings will
be documented. If the tumour is resectable the resected specimen will be sent for HPE.In the
event of only palliative bypass surgery any tissue sampling obtained during the surgery will be
sent for the same.After histopathological confirmation of the diagnosis,the correlation between
CA 19-9 and tumour respectability is analyzed.
The results arising from this study will be analyzed and used for academic purposes.
You will be given clear instructions at every step and you are free to ask/ clarify any doubts.
Your identity will remain confidential. You are free to withdraw from this trial at any point of
time, without any prior notice &/ or without any medical or legal implications.
I request you to volunteer for this study.
Thanking You,
Investigator’s Sign Patient’s Sign
(Dr. APARNA .M.J) (Name: )
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Role of CA 19-9 in predicting tumor resectability in cancer
head of pancreas
Investigator : Dr. APARNA M.J, PGY3 – MS (Gen Surg)
Guide : Prof. Dr. P. Darwin, Chief, Unit S1.
____________________________________________________________________________
Informed Consent
Name: Age/ Sex: IP:
I herewith declare that I have been explained in a language fully understood by
me regarding the purpose of this study, methodology, proposed intervention, plausible
side effects, if any and sequelae.
I have been given an opportunity to discuss my doubts and I have received the
appropriate explanation.
I understand that my participation in this study is completely voluntary and that I am
free to withdraw from this study at anytime without any prior notice &/ or without
having my medical or legal rights affected.
I permit the author and the research team full access to all my records at any point,
even if I have withdrawn from the study. However my identity will not be revealed to
any third party or publication.
I herewith permit the author and the research team to use the results and conclusions
arising from this study for any academic purpose, including but not limited to
dissertation/ thesis or publication or presentation in any level.
Therefore, in my full conscience, I give consent to be included in the study and to
undergo any investigation or any intervention therein.
Patient’s Sign Investigator’s Sign
(Dr. APARNA .M.J)
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S.NO. NAME AGE/SEX IP.NO.
CA 19-
9
CECT/MRCP
FINDINGS
CECT/MRCP
FINDINGS
OPERATIVE
FINDINGS
SURGERY
DONE
HISTOPATHOLOGY
REPORT
MASS
LESION SMA ENMT.
SMPV
INFILT.
LIVER
METS ASCITES
1 ANDAL 65/F 43267 32 Present - - - -
Growth in the
HOP without
local
spread/mets
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
2 MAHALAKSHMI 58/F 76140 30 Present - - - -
Growth in the
HOP without
local
spread/mets
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
3 VARADAN 66/M 33410 765 Present + - - -
Growth in the
HOP ,with
infiltration into
SMA
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
4 MALAR 38/F 33954 24 Present - - - -
Growth in the
HOP without
local
spread/mets
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
5 PONNAMMAL 53/F 10343 28 Present - + - -
Growth in the
HOP,with
infiltration of
SMPV junction
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
6 NAVEEN 52/M 32190 34 Present - - + +
Growth in the
HOP,with
multiple liver
deposits,ascites
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
7 MUPPIDATHI 36/F 41982 30 Present - - - -
Growth in the
HOP without
local
spread/mets
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
109
8 THAHIRA 40/F 33501 25 Present - - - -
Lcally advanced
growth
infiltrating into
portal vein
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
9 RANGANAYAKI 35/F 11972 23 Present - + - -
Growth in the
HOP,with
infiltration of
SMPV junction
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
10 LAKSHMI 55/F 12844 23 Present - - - -
Locally
advanced
growth with
peritoneal,liver
deposits
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
11 IRULAPPAN 80/M 15593 17 Present - - - -
Growth in the
HOP without
local
spread/mets
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
12 ELAMMAL 65/F 17601 234 Present - - - -
Growth in the
HOP with
infiltration into
SMA,SMV
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
13 VARADHAN 65/M 28886 36 Present - - - -
Locally
advanced
growth with
peritoneal,liver
deposits
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
14 SAIT 32/M 24535 19 Present - - - -
Growth in the
HOP,with direct
infiltration of
SMPV jn.
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
15 SHAKUNTHALA 60/F 24549 974 Present - - - -
Growth in the
HOP without
local
spread/mets
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
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16 BASKAR 65/M 26687 26 Present - - - -
locally
infiltrated
growth with
fixity to
SMA,SMV
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
17 MUGUNTHAN 44/M 30093 12000 Present - - - -
Growth in the
HOP without
local
spread/mets
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
18 YASODAMMAL 60/F 32807 22 Present - - - -
Locally
advanced
growth with
peritoneal,liver
deposits
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
19 GANAPATHY 51/M 13329 29 Present - - + +
Growth in the
HOP, with
extensive liver
mets,ascites
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
20 GNANAKRISHNAN 46/M 39220 834 Present - - - -
Growth in
HOP,with
involvement
upto porta
hepatis
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
21 NITHYA 47/F 39122 16 Present - - - -
Growth in the
HOP without
local
spread/mets
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
22 MUNIYAPPAN 60/M 36739 50000 Present - - - -
Growth in the
HOP without
local
spread/mets
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
23 SADAIYYAN 54/M 19669 37 Present - - - -
Growth in the
HOP without
local
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
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spread/mets
24 THANIGAIVELU 65/M 36779 24 Present - - - -
Growth in the
HOP with
extensive
infiltration of PV
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
25 CHANDRABABU 67/M 29011 28 Present - - + +
Growth in the
HOP with
deposits in
liver,peritoneum
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
26 SADAYAMMAL 38/F 28044 26 Present - - - -
Growth in the
HOP without
local
spread/mets
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
27 MUNUSAMY 64/M 25679 2567 Present - - - -
Growth in the
HOP without
local
spread/mets
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
28 PAPPANAIDU 59/M 15673 18 Present + - - -
Growth in the
HOP,with
encasement of
SMA,ascites
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
29 PENICILAIYYA 62/M 36789 7643 Present - + - -
Growth in the
HOP,with
infiltration of
SMPV junction
PALLIATIVE
BYPASS
INFILTRATING
ADENOCARCINOMA
30 DEVAKI 43/F 16578 432 Present - - - -
Growth in the
HOP without
local
spread/mets
WHIPPLES
PROCEDURE
INFILTRATING
ADENOCARCINOMA
